Additional Positive Interim Results from Nanoform's Clinical Study USA - English Share this article Share this article HELSINKI, Feb. 24, 2021 /PRNewswire/ -- Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced further positive interim results from its ongoing clinical study. The fast absorption data implies that small is powerful ® and might offer viable alternatives to complex formulation approaches such as cyclodextrin based technologies. Nanoform has received the second interim pharmacokinetic (PK) study results related to its Phase 1, single-centre, part crossover, open-label, partially-randomised study designed to evaluate the PK profile of piroxicam following administration of nanoformed oral immediate release (IR) piroxicam tablet and IR reference products in healthy subjects (UNICORN).